These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16988582)

  • 41. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
    Jackman DM; Chirieac LR; Jänne PA
    Semin Respir Crit Care Med; 2005 Jun; 26(3):342-52. PubMed ID: 16052436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of EGFR targeted therapy.
    Baselga J
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):218-9. PubMed ID: 16224409
    [No Abstract]   [Full Text] [Related]  

  • 43. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
    Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
    Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
    Papageorgio C; Perry MC
    Cancer Invest; 2007 Oct; 25(7):647-57. PubMed ID: 18027154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Side effects of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)].
    Takeda K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():245-9. PubMed ID: 25831761
    [No Abstract]   [Full Text] [Related]  

  • 46. Rationale for investigation of epidermal growth factor receptor inhibitors in definitive treatment of locally advanced non-small cell lung cancer and head and neck cancer.
    Choy H; Kim DW
    Semin Respir Crit Care Med; 2004; 25 Suppl 1():33-43. PubMed ID: 16088519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.
    Krause M; Gurtner K; Deuse Y; Baumann M
    Int J Radiat Biol; 2009 Nov; 85(11):943-54. PubMed ID: 19895271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
    Wierzbicka E; Tourani JM; Guillet G
    Br J Dermatol; 2006 Jul; 155(1):213-4. PubMed ID: 16792781
    [No Abstract]   [Full Text] [Related]  

  • 49. Novel targets in gastric and esophageal cancer.
    Valverde CM; Macarulla T; Casado E; Ramos FJ; Martinelli E; Tabernero J
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):128-38. PubMed ID: 16829119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
    Cohen SJ; Cohen RB; Meropol NJ
    J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting phosphoinositide 3-kinase signalling in lung cancer.
    Wojtalla A; Arcaro A
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):278-90. PubMed ID: 21316260
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cell signaling molecules as drug targets in lung cancer: an overview.
    Mukherjee TK; Paul K; Mukhopadhyay S
    Curr Opin Pulm Med; 2011 Jul; 17(4):286-91. PubMed ID: 21537189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Targeted therapy in non-small cell lung tumors: recent findings and future perspectives].
    Conte PF; Barbieri F
    Pathologica; 2005 Aug; 97(4):172-3. PubMed ID: 16440637
    [No Abstract]   [Full Text] [Related]  

  • 54. P2 receptors and cancer.
    White N; Burnstock G
    Trends Pharmacol Sci; 2006 Apr; 27(4):211-7. PubMed ID: 16530853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
    Hegi ME; Rajakannu P; Weller M
    Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermal growth factor receptor pathway.
    Bonomi P
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S470-1. PubMed ID: 21102243
    [No Abstract]   [Full Text] [Related]  

  • 57. Novel therapies in lung cancer.
    Hahn O; Salgia R
    Hematol Oncol Clin North Am; 2005 Apr; 19(2):343-67, vii. PubMed ID: 15833410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecularly targeted approaches to the chemoprevention of lung cancer.
    Khuri FR; Cohen V
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4249s-4253s. PubMed ID: 15217968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.
    Jimeno A; Hidalgo M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):727-35. PubMed ID: 16111472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy and targeted agents for thymic malignancies.
    Girard N
    Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.